1. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Del Rev. 2012;64:83-101.
2. Selvamuthukumar S, Anandam S, Krishnamoorthy K, Rajappan M. Nanosponges: A novel class of drug delivery system-review. J Pharm Pharm Sci. 2012;15(1):103-111.
3. Arias J, Gallardo V, Gomez-Lopera S, Plaza R, Delgado A. Synthesis and characterization of poly (ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. Journal of Controlled Release. 2001;77(3):309-321.
4. Lherm C, Müller RH, Puisieux F, Couvreur P. Alkylcyanoacrylate drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. Int J Pharm. 1992;84(1):13-22.
5. H Muller R, Shegokar R, M Keck C. 20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications. Curr Drug Disc Technol. 2011;8(3):207-227.
6. Jores K, Mehnert W, Mäder K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharm Res. 2003;20(8):1274-1283.
7. Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. Drug development and industrial pharmacy. 2008;34(12):1394-1405.
8. Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)–structural investigations on two different carrier systems. Bio-medical materials and engineering. 2005;15(5):393-402.
9. Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199(2):167-177.
10. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. Journal of controlled release. 2012;163(1):34-45.
11. Hauss DJ. Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs: CRC Press; 2007.
12. Emami J, Rezazadeh M, Varshosaz J, Tabbakhian M, Aslani A. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: a detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. Journal of Nanomaterials. 2012;2012.
13. Jia L, Zhang D, Li Z, Duan C, Wang Y, Feng F, et al. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces. 2010;80(2):213-218.
14. Xia Q, Kong R, editors. Freeze-drying and characterization of vitamin a palmitate-loaded nanostructured lipid carriers (NLC). Materials Science Forum; 2011: Trans Tech Publ.
15. Hentschel A, Gramdorf S, Müller R, Kurz T. β‐Carotene‐loaded nanostructured lipid carriers. J Food Sci. 2008;73(2):N1-N6.
16. Dubey A, Prabhu P, Kamath J. Nano Structured lipid carriers: A Novel Topical drug delivery system. International Journal of PharmTech Research. 2012;4(2):705-714.
17. Bunjes H, Koch MH, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci. 2003;92(7):1509-1520.
18. Han F, Li S, Yin R, Liu H, Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf Physicochem Eng Aspects. 2008;315(1-3):210-216.
19. Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T, et al. Update of the LIPID MAPS comprehensive classification system for lipids. Journal of lipid research. 2009;50:S9-S14.
20. Coleman RA, Lee DP. Enzymes of triacylglycerol synthesis and their regulation. Progress in lipid research. 2004;43(2):134-176.
21. Honke K, Zhang Y, Cheng X, Kotani N, Taniguchi N. Biological roles of sulfoglycolipids and pathophysiology of their deficiency. Glycoconjugate journal. 2004;21(1):59-62.
22. Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006;580(23):5533-5540.
23. Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chemistry and physics of lipids. 2000;106(1):1-29.
24. Dickson RC. Sphingolipid functions in Saccharomyces cerevisiae: comparison to mammals. Annual review of biochemistry. 1998;67:27.
25. Maula T. Membrane properties of structurally modified ceramides: effects on lipid lateral distribution and sphingomyelin-interactions in artificial bilayer membranes. 2014.
26. Hori T, Sugita M. Sphingolipids in lower animals. Progress in lipid research. 1993;32(1):25-45.
27. Bach D, Wachtel E. Phospholipid/cholesterol model membranes: formation of cholesterol crystallites. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2003;1610(2):187-197.
28. Villinski JC, Hayes JM, Brassell SC, Riggert VL, Dunbar RB. Sedimentary sterols as biogeochemical indicators in the Southern Ocean. Organic Geochemistry. 2008;39(5):567-588.
29. Rao AV, Rao LG. Carotenoids and human health. Pharmacol Res. 2007;55(3):207-216.
30. Kuzuyama T, Seto H. Diversity of the biosynthesis of the isoprene units. Natural product reports. 2003;20(2):171-183.
31. Raetz CR, Guan Z, Ingram BO, Six DA, Song F, Wang X, et al. Discovery of new biosynthetic pathways: the lipid A story. Journal of lipid research. 2009;50:S103-S108.
32. Walsh CT. Polyketide and nonribosomal peptide antibiotics: modularity and versatility. Science. 2004;303(5665):1805-1810.
33. Minto RE, Blacklock BJ. Biosynthesis and function of polyacetylenes and allied natural products. Progress in lipid research. 2008;47(4):233-306.
34. Bhattacharyya L, Schuber S, Sheehan C, William R. Excipients: background/introduction. Excipient development for pharmaceutical, biotechnology, and drug delivery systems. 2006:1-3.
35. Apte SP, Ugwu SO. A review and classification of emerging excipients in parenteral medications. Pharm Technol. 2003;27(3):46-46.
36. Wang J, Wen H, Desai D. Lubrication in tablet formulations. Eur J Pharm Biopharm. 2010;75(1):1-15.
37. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995;12(11):1561-1572.
38. Cannon J, Long M. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery–Part II: Oral applications. Water-insoluble drug formulation Boca Raton: CRC. 2008:227-253.
39. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’drug delivery systems. Eur J Pharm Sci. 2000;11:S93-S98.
40. Zgair A, Wong JC, Lee JB, Mistry J, Sivak O, Wasan KM, et al. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American journal of translational research. 2016;8(8):3448.
41. Wasan EK, Gershkovich P, Zhao J, Zhu X, Werbovetz K, Tidwell RR, et al. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model. PLoS Negl Trop Dis. 2010;4(12):e913.
42. Gershkovich P, Wasan EK, Sivak O, Li R, Zhu X, Werbovetz KA, et al. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. J Antimicrob Chemother. 2010;65(3):535-537.
43. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. Journal of controlled release. 2008;129(1):1-10.
44. Savla R, Browne J, Plassat V, Wasan KM, Wasan EK. Review and analysis of FDA approved drugs using lipid-based formulations. Drug development and industrial pharmacy. 2017;43(11):1743-1758.
45. Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, et al. 50 years of oral lipid-based formulations: provenance, progress and future perspectives. Adv Drug Del Rev. 2016;101:167-194.
46. Chen X-Q, Gudmundsson OS, Hageman MJ. Application of lipid-based formulations in drug discovery. J Med Chem. 2012;55(18):7945-7956.
47. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Del Rev. 1997;25(1):47-58.
48. Yalkowsky SH, Flynn G, Amidon G. Solubility of nonelectrolytes in polar solvents. J Pharm Sci. 1972;61(6):983-984.
49. Patel DP, Li P, Serajuddin AT. Enhanced microemulsion formation in lipid-based drug delivery systems by combining mono-esters of mediumchain fatty acids with di-or tri-esters. Journal of Excipients and Food Chemicals. 2016;3(2):1113.
50. Rane SS, Anderson BD. What determines drug solubility in lipid vehicles: is it predictable? Adv Drug Del Rev. 2008;60(6):638-656.
51. Anderson BD, Rytting JH, Higuchi T. Solubility of polar organic solutes in nonaqueous systems: role of specific interactions. J Pharm Sci. 1980;69(6):676-680.
52. Elder D, Holm R. Aqueous solubility: simple predictive methods (in silico, in vitro and bio-relevant approaches). Int J Pharm. 2013;453(1):3-11.
53. Persson LC, Porter CJ, Charman WN, Bergström CA. Computational prediction of drug solubility in lipid based formulation excipients. Pharm Res. 2013;30(12):3225-3237.
54. Rane SS, Anderson BD. Molecular dynamics simulations of functional group effects on solvation thermodynamics of model solutes in decane and tricaprylin. Mol Pharm. 2008;5(6):1023-1036.
55. Egberts E, Marrink S-J, Berendsen HJ. Molecular dynamics simulation of a phospholipid membrane. European biophysics journal. 1994;22(6):423-436.
56. Kandt C, Ash WL, Tieleman DP. Setting up and running molecular dynamics simulations of membrane proteins. Methods. 2007;41(4):475-488.
57. Khelashvili G, Pabst G, Harries D. Cholesterol orientation and tilt modulus in DMPC bilayers. The Journal of Physical Chemistry B. 2010;114(22):7524-7534.
58. Marrink S, Jähnig F, Berendsen H. Proton transport across transient single-file water pores in a lipid membrane studied by molecular dynamics simulations. Biophysical journal. 1996;71(2):632-647.
59. Birru WA, Warren DB, Ibrahim A, Williams HD, Benameur H, Porter CJ, et al. Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components. Mol Pharm. 2014;11(8):2825-2834.
60. King DT, Warren DB, Pouton CW, Chalmers DK. Using molecular dynamics to study liquid phase behavior: simulations of the ternary sodium laurate/sodium oleate/water system. Langmuir. 2011;27(18):11381-11393.
61. Tyagi P, Subramony JA. Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small. Journal of Controlled Release. 2018;272:159-168.
62. Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian journal of pharmaceutical sciences. 2014;9(6):304-316.
63. Liu L, Ye Q, Lu M, Lo Y-C, Hsu Y-H, Wei M-C, et al. A new approach to reduce toxicities and to improve bioavailabilities of platinum-containing anti-cancer nanodrugs. Sci Rep. 2015;5(1):1-11.
64. Kim K, Kwon T, Sung BJ, Kim C. Effect of methane–sugar interaction on the solubility of methane in an aqueous solution. Journal of colloid and interface science. 2017;500:113-118.
65. Liu S, Cao S, Hoang K, Young KL, Paluch AS, Mobley DL. Using MD simulations to calculate how solvents modulate solubility. J Chem Theory Comput. 2016;12(4):1930-1941.
66. Li L, Totton T, Frenkel D. Computational methodology for solubility prediction: Application to the sparingly soluble solutes. The Journal of chemical physics. 2017;146(21):214110.
67. Mehta CH, Narayan R, Nayak UY. Computational modeling for formulation design. Drug Discovery Today. 2019;24(3):781-788.
68. Gaikwad VL, Bhatia NM, Desai SA, Bhatia MS. Quantitative structure property relationship modeling of excipient properties for prediction of formulation characteristics. Carbohydr Polym. 2016;151:593-599.
69. Khalid MH, Kazemi P, Perez-Gandarillas L, Michrafy A, Szlęk J, Jachowicz R, et al. Computational intelligence models to predict porosity of tablets using minimum features. Drug Des Devel Ther. 2017;11:193.
70. Pathan S, Ali S, Shrivastava M. Quantitative structure activity relationship and drug design: A Review. Int J Res Biosciences. 2016;5(4):1-5.
71. Abdel-Ilah L, Veljović E, Gurbeta L, Badnjević A. Applications of QSAR study in drug design. International Journal of Engineering Research & Technology (IJERT). 2017;6(06).
72. Gaikwad VL, Bhatia MS, Singhvi I. Experimental and chemoinformatics evaluation of some physicochemical properties of excipients influencing release kinetics of the acidic drug ibuprofen. Chemosphere. 2015;138:494-502.
73. Hospital A, Goñi JR, Orozco M, Gelpí JL. Molecular dynamics simulations: advances and applications. Advances and applications in bioinformatics and chemistry: AABC. 2015;8:37.
74. Veljović E, Špirtović-Halilović S, Muratović S, Osmanović A, Badnjević A, Gurbeta L, et al. Artificial neural network and docking study in design and synthesis of xanthenes as antimicrobial agents. CMBEBIH 2017: Springer; 2017. p. 617-626.
75. Wu W, Zhang C, Lin W, Chen Q, Guo X, Qian Y, et al. Quantitative structure-property relationship (QSPR) modeling of drug-loaded polymeric micelles via genetic function approximation. PLoS One. 2015;10(3):e0119575.
76. Metwally AA, Hathout RM. Computer-assisted drug formulation design: novel approach in drug delivery. Mol Pharm. 2015;12(8):2800-2810.
77. Suys EJ, Warren DB, Porter CJ, Benameur H, Pouton CW, Chalmers DK. Computational models of the intestinal environment. 3. The impact of cholesterol content and pH on mixed micelle colloids. Mol Pharm. 2017;14(11):3684-3697.
78. Birru WA, Warren DB, Headey SJ, Benameur H, Porter CJ, Pouton CW, et al. Computational models of the gastrointestinal environment. 1. The effect of digestion on the phase behavior of intestinal fluids. Mol Pharm. 2017;14(3):566-579.
79. Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315-499.
80. Kumar CS. Nanotechnology Characterization Tools for Tissue Engineering and Medical Therapy: Springer; 2019.
81. Páll S, Abraham MJ, Kutzner C, Hess B, Lindahl E, editors. Tackling exascale software challenges in molecular dynamics simulations with GROMACS. International conference on exascale applications and software; 2014: Springer.
82. Benson SP, Pleiss Jr. Molecular dynamics simulations of self-emulsifying drug-delivery systems (SEDDS): influence of excipients on droplet nanostructure and drug localization. Langmuir. 2014;30(28):8471-8480.
83. Alskär LC, Porter CJ, Bergström CA. Tools for early prediction of drug loading in lipid-based formulations. Mol Pharm. 2016;13(1):251-261.
84. Zheng W, Jain A, Papoutsakis D, Dannenfelser R-M, Panicucci R, Garad S. Selection of oral bioavailability enhancing formulations during drug discovery. Drug development and industrial pharmacy. 2012;38(2):235-247.
85. Porter CJ, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Del Rev. 2008;60(6):673-691.
86. Lin L, Wong H. Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models. Pharmaceutics. 2017;9(4):41.
87. Do Thi T, Van Speybroeck M, Barillaro V, Martens J, Annaert P, Augustijns P, et al. Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. Eur J Pharm Sci. 2009;38(5):479-488.
88. Patel SV, Patel S. Prediction of the solubility in lipidic solvent mixture: investigation of the modeling approach and thermodynamic analysis of solubility. Eur J Pharm Sci. 2015;77:161-169.
89. Bunjes H, Müller-Goymann C. Microsystems for emulsification. Microsystems for Pharmatechnology: Springer; 2016. p. 153-179.
90. Sacchetti M, Nejati E. Prediction of drug solubility in lipid mixtures from the individual ingredients. AAPS PharmSciTech. 2012;13(4):1103-1109.
91. Lu D, Aksimentiev A, Shih AY, Cruz-Chu E, Freddolino PL, Arkhipov A, et al. The role of molecular modeling in bionanotechnology. Physical Biology. 2006;3(1):S40.
92. Yadav N, Khatak S, Sara US. Solid lipid nanoparticles-a review. Int J Appl Pharm. 2013;5(2):8-18.
93. Cabrera I, Abasolo I, Corchero JL, Elizondo E, Gil PR, Moreno E, et al. α‐Galactosidase‐a loaded‐nanoliposomes with enhanced enzymatic activity and intracellular penetration. Advanced healthcare materials. 2016;5(7):829-840.
94. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomed Nanotechnol Biol Med. 2016;12(1):143-161.
95. Houacine C, Adams D, Singh KK. Impact of liquid lipid on development and stability of trimyristin nanostructured lipid carriers for oral delivery of resveratrol. J Mol Liq. 2020;316:113734.
96. Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, et al. Nanoemulsion: Concepts, development and applications in drug delivery. Journal of controlled release. 2017;252:28-49.
97. Dantas IL, Bastos KTS, Machado M, Galvão JG, Lima AD, Gonsalves JKMC, et al. Influence of stearic acid and beeswax as solid lipid matrix of lipid nanoparticles containing tacrolimus. Journal of Thermal Analysis and Calorimetry. 2018;132(3):1557-1566.
98. Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86(1):7-22.
99. Huang J, Wang Q, Li T, Xia N, Xia Q. Nanostructured lipid carrier (NLC) as a strategy for encapsulation of quercetin and linseed oil: Preparation and in vitro characterization studies. J Food Eng. 2017;215:1-12.
100. Sznitowska M, Wolska E, Baranska H, Cal K, Pietkiewicz J. The effect of a lipid composition and a surfactant on the characteristics of the solid lipid microspheres and nanospheres (SLM and SLN). Eur J Pharm Biopharm. 2017;110:24-30.
101. Deshpande KB. Formulation and evaluation of lipid nanoparticles enriched gel for transdermal delivery of Aspirin. 2015.
102. Chinsriwongkul A, Chareanputtakhun P, Ngawhirunpat T, Rojanarata T, Sila-on W, Ruktanonchai U, et al. Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug. AAPS PharmSciTech. 2012;13(1):150-158.
103. Silva A, González-Mira E, García M, Egea M, Fonseca J, Silva R, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces. 2011;86(1):158-165.
104. Zoubari G, Staufenbiel S, Volz P, Alexiev U, Bodmeier R. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery. Eur J Pharm Biopharm. 2017;110:39-46.
105. Chen C-C, Tsai T-H, Huang Z-R, Fang J-Y. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm. 2010;74(3):474-482.
106. Boreham A, Volz P, Peters D, Keck CM, Alexiev U. Determination of nanostructures and drug distribution in lipid nanoparticles by single molecule microscopy. Eur J Pharm Biopharm. 2017;110:31-38.
107. Jores K, Haberland A, Wartewig S, Mäder K, Mehnert W. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm Res. 2005;22(11):1887-1897.
108. Tikekar RV, Nitin N. Distribution of encapsulated materials in colloidal particles and its impact on oxidative stability of encapsulated materials. Langmuir. 2012;28(25):9233-9243.
109. Dan N. Compound release from nanostructured lipid carriers (NLCs). J Food Eng. 2016;171:37-43.
110. Esposito E, Drechsler M, Puglia C, Cortesi R. New strategies for the delivery of some natural anti-oxidants with therapeutic properties. Mini Rev Med Chem. 2019;19(13):1030-1039.
111. Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis. 2012;11(1):1-8.
112. Dan N. Nanostructured lipid carriers: effect of solid phase fraction and distribution on the release of encapsulated materials. Langmuir. 2014;30(46):13809-13814.
113. Rog T, Bunker A. Mechanistic understanding from molecular dynamics simulation in pharmaceutical research 1: drug delivery. Frontiers in Molecular Biosciences. 2020;7:371.
114. Khalkhali M, Mohammadinejad S, Khoeini F, Rostamizadeh K. Vesicle-like structure of lipid-based nanoparticles as drug delivery system revealed by molecular dynamics simulations. Int J Pharm. 2019;559:173-181.
115. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1:19-25.
116. Smith TR, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nature communications. 2020;11(1):1-13.
117. Kou L, Bhutia YD, Yao Q, He Z, Sun J, Ganapathy V. Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Front Pharmacol. 2018;9:27.
118. Kulkarni JA, Witzigmann D, Leung J, Tam YYC, Cullis PR. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale. 2019;11(45):21733-21739.
119. Scheetz L, Park KS, Li Q, Lowenstein PR, Castro MG, Schwendeman A, et al. Engineering patient-specific cancer immunotherapies. Nature biomedical engineering. 2019;3(10):768-782.
120. Gehr P, Zellner R. Biological Responses to Nanoscale Particles: Springer; 2019.
121. Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37(10):1174-1185.
122. Wei L, Zhao Y, Hu X, Tang L. Redox-responsive polycondensate neoepitope for enhanced personalized cancer vaccine. ACS central science. 2020;6(3):404-412.
123. Yue J, Feliciano TJ, Li W, Lee A, Odom TW. Gold nanoparticle size and shape effects on cellular uptake and intracellular distribution of siRNA nanoconstructs. Bioconjugate chemistry. 2017;28(6):1791-1800.
124. Yamada Y, Fukuda Y, Sasaki D, Maruyama M, Harashima H. Development of a nanoparticle that releases nucleic acids in response to a mitochondrial environment. Mitochondrion. 2020;52:67-74.
125. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nature reviews Drug discovery. 2009;8(2):129-138.
126. Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Del Rev. 2016;99:129-137.
127. Chen WH, Luo GF, Zhang XZ. Recent advances in subcellular targeted cancer therapy based on functional materials. Adv Mater. 2019;31(3):1802725.
128. Guan S, Munder A, Hedtfeld S, Braubach P, Glage S, Zhang L, et al. Self-assembled peptide–poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nature nanotechnology. 2019;14(3):287-297.